ArticlePloS one2011
Reactive oxygen species production and mitochondrial dysfunction contribute to quercetin induced death in Leishmania amazonensis.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 2 syntheses or guidelines pooled it, 191 citations in OpenAlex.
- Antileishmanial Activity of Bioactive Compounds Obtained fromMolecules (Basel, Switzerland) · 2026Pooled it
- Can floral nectars reduce transmission of Leishmania?PLoS neglected tropical diseases · 2022Pooled it
- Mechanistic evaluation of niosomal Rhoifolin in antileishmanial therapy and its additive potential with meglumine antimoniate.Scientific reports · 2026Article
- TargetingMetabolites · 2026Article
- Article
- Efficacy of a Hemolymph-Based Cream Derived fromJournal of arthropod-borne diseases · 2026Article
- Natural product-based therapeutic strategies againstFrontiers in microbiology · 2026Review
- Eprinomectin InhibitsTransboundary and emerging diseases · 2026Article
- Dual immunomodulatory and antileishmanial potential of TLR7/8 agonists againstInfection and immunity · 2025Article
- Article
- Biocompatibility and antioxidant effects of hydroxyapatite-quercetin composites: in vitro and in ovo studies.Scientific reports · 2025Article
- Oxidative Stress and Survival ofExpert reviews in molecular medicine · 2025Review
- Article
- Plant-derived products as anti-leishmanials which target mitochondria: a review.Expert reviews in molecular medicine · 2025Review
- In Vitro Inhibitory Activity of Corilagin and Punicalagin AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Biocompatibility and Effectiveness of Amphotericin B-Loaded Metal-Organic Structures (AmB-ZIF-8) as Dermal Drug Transporters in Experimental Cutaneous Leishmaniasis.Journal of experimental pharmacology · 2025Article
- Piperine, quercetin, and curcumin identified as promising natural products for topical treatment of cutaneous leishmaniasis.Parasitology research · 2024Article
- Anti-Antimicrobial agents and chemotherapy · 2024Article
- Apigeninidin chloride disruptsFrontiers in cellular and infection microbiology · 2024Article
- Quercetin as a Promising Antiprotozoan Phytochemical: Current Knowledge and Future Research Avenues.BioMed research international · 2024Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeishmaniasis, a parasitic disease caused by protozoa of the genus Leishmania, affects more than 12 million people worldwide. Quercetin has generated considerable interest as a pharmaceutical compound with a wide range of therapeutic activities. One such activity is exhibited against the bloodstream parasite Trypanosoma brucei and amastigotes of Leishmania donovani. However, the mechanism of protozoan action of quercetin has not been studied. METHODOLOGY/PRINCIPAL
findingsIn the present study, we report here the mechanism for the antileishmanial activity of quercetin against Leishmania amazonensis promastigotes. Quercetin inhibited L. amazonensis promastigote growth in a dose- and time- dependent manner beginning at 48 hours of treatment and with maximum growth inhibition observed at 96 hours. The IC(50) for quercetin at 48 hours was 31.4 µM. Quercetin increased ROS generation in a dose-dependent manner after 48 hours of treatment. The antioxidant GSH and NAC each significantly reduced quercetin-induced cell death. In addition, quercetin caused mitochondrial dysfunction due to collapse of mitochondrial membrane potential. CONCLUSIONS/SIGNIFICANCE: The effects of several drugs that interfere directly with mitochondrial physiology in parasites such as Leishmania have been described. The unique mitochondrial features of Leishmania make this organelle an ideal drug target while minimizing toxicity. Quercetin has been described as a pro-oxidant, generating ROS which are responsible for cell death in some cancer cells. Mitochondrial membrane potential loss can be brought about by ROS added directly in vitro or induced by chemical agents. Taken together, our results demonstrate that quercetin eventually exerts its antileishmanial effect on L. amazonensis promastigotes due to the generation of ROS and disrupted parasite mitochondrial function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.